2016-03-28 16:00:25 UTC

Research Supports Statins as Chemopreventive Agent for IBD Patients

March 29, 2016

CGH article in press finds that statin use is associated with reduced risk of colorectal cancer in IBD patients.

Patients with long-standing ulcerative colitis and colonic Crohn’s disease have a two-fold increase in risk of colorectal cancer compared with the general population. Finding a chemopreventive agent for this group is a top priority. A new Clinical Gastroenterology and Hepatology (CGH) article in press finds that, based on a large IBD cohort, statin use is associated inversely with the risk of CRC. This research encourages future studies on the role of statins as chemopreventive agents.

The research team, led by Ashwin N. Ananthakrishnan, MBBS, MPH, from Massachusetts General Hospital, Boston, collected data from 11,001 patients with IBD receiving care at hospitals in the Greater Boston metropolitan area from 1998 through 2010. In the cohort, 12.5 percent of patients received one or more prescriptions for a statin. Patients using statins were more likely to be older, male, white, smokers and have greater comorbidity than nonusers. Over a follow-up period of 9 years, 2 percent of statin users developed CRC compared with 3 percent of non-statin-users. On multivariate analysis, statin use remained independently and inversely associated with CRC.

To read the latest literature on chemopreventive agents for colorectal cancer, review the full article on the CGH website (login required).

More on Colorectal Cancer

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Advocate CMS, close the colonoscopy loophole

March 8, 2018

AGA urges CMS to address the cost sharing problem that arises when screening colonoscopies become diagnostic for Medicare patients.